Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
University of Alberta
$65,000.00
Role of leupaxin in regulating the immune response to breast cancer
EF 2023-24
Résumé
Killer T cells of the immune system are an effective weapon against cancer since they can reduce tumor growth and limit metastasis. They are white blood cells that move around the body to directly kill cancer cells. However, these cells are not always able to keep up with the growing tumor and many tumors suppress their activity, particularly in breast cancer. We predicted a molecule called leupaxin might normally limit the function of killer T cells. When we engineered mice that no longer have leupaxin, we found that their killer T cells reduced the size of tumors and even cleared some tumors. For this project we will determine why killer T cells from these mice are better able to control breast tumor growth. These studies may pave the way for a new therapeutic approach to treat cancer.
Programme
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
516997
Name
Ostergaard Hanne L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Role of leupaxin in regulating the immune response to breast cancer
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Breast Cancer
Abstract
Killer T cells of the immune system are an effective weapon against cancer since they can reduce tumor growth and limit metastasis. They are white blood cells that move around the body to directly kill cancer cells. However, these cells are not always able to keep up with the growing tumor and many tumors suppress their activity, particularly in breast cancer. We predicted a molecule called leupaxin might normally limit the function of killer T cells. When we engineered mice that no longer have leupaxin, we found that their killer T cells reduced the size of tumors and even cleared some tumors. For this project we will determine why killer T cells from these mice are better able to control breast tumor growth. These studies may pave the way for a new therapeutic approach to treat cancer.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ostergaard, Hanne L
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~